Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115104 | 0.85 | L3MBTL1 (0.43) | L3MBTL1NPC1EGLN1KLKB1KLK1 | |
| SCHEMBL4106191 | 0.83 | L3MBTL1 (0.49) | L3MBTL1NPC1MAPTALDH1A1KDM4E | |
| SCHEMBL4110150 | 0.83 | L3MBTL1 (0.49) | L3MBTL1MAPTALDH1A1HPGDGLA | |
| SCHEMBL4118608 | 0.69 | L3MBTL1 (0.33) | L3MBTL1NPC1ALDH1A1KDM5AKDM4E | |
| SCHEMBL4104664 | 0.69 | P2RY12 (0.34) | L3MBTL1NPC1ALDH1A1KDM5AKDM4E | |
| SCHEMBL949202 | 0.66 | TSHR (0.39) | NPC1MAPTALDH1A1HPGDGLA | |
| SCHEMBL23163199 | 0.65 | SMN1; SMN2 (0.41) | NPC1MAPTALDH1A1PKMKDM4E | |
| SCHEMBL17796240 | 0.63 | ALDH1A1 (0.34) | NPC1MAPTALDH1A1HPGDGLA | |
| SCHEMBL15747072 | 0.63 | NPC1 (0.43) | NPC1EGLN1MAPT | |
| SCHEMBL4882220 | 0.62 | ALDH1A1 (0.38) | L3MBTL1MAPTALDH1A1HPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | L3MBTL1 4838/4885NPC1 3171/4885EGLN1 2894/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | L3MBTL1 4877/4885NPC1 3970/4885EGLN1 2033/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | L3MBTL1 4857/4885NPC1 3327/4885EGLN1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.